Filing Flows › HCW Biologics (HCWB) › Q2 2026 › vs Q1 2026
HCW Biologics (HCWB) Q2 2026 vs Q1 2026 (quarter over quarter)
HCW Biologics's revenue fell $6.4M (-98%) from $6.5M in Q1 2026 to $136K in Q2 2026.
HCW Biologics, Q2 2026: revenue $136K (21× year over year), net loss $5.2M, operating cash flow −$4.0M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $136K | $6.5M | −$6.4M | -98% |
| Net loss | $5.2M | −$3.5M | $8.7M | — |
| Costs & expenses | $5.4M | $7.1M | −$1.8M | -25% |
| Operating costs | $3.3M | $3.3M | −$5K | -0.2% |
| Interest & other, net | $2.1M | −$567K | $2.6M | — |
| Research & development | $1.2M | $1.3M | −$55K | -4% |
| General & admin | $1.9M | $1.8M | $37K | +2% |
| Operating cash sources | $5.2M | −$3.5M | $8.7M | — |
| Depreciation & amortization | $127K | $142K | −$15K | -11% |
| Share-based compensation | $1K | $10K | −$9K | -88% |
| Working capital & other | $1.1M | −$5.2M | $6.3M | — |
| Cash used in operations | $4.0M | $1.6M | $2.4M | +152% |
| Net loss absorbed | $5.2M | −$3.5M | $8.7M | — |
Questions
How much did HCW Biologics's revenue grow quarter over quarter in Q2 2026?
HCW Biologics's revenue fell $6.4M (-98%) from $6.5M in Q1 2026 to $136K in Q2 2026.